Weight administration medicines, together with Wegovy, Zepbound and Foundayo, might be obtainable to eligible Medicare beneficiaries with a $50 copay beginning July.
Common Photographs Group/Getty Photographs
conceal caption
toggle caption
Common Photographs Group/Getty Photographs
Beginning in July, Medicare beneficiaries might be able to get a GLP-1 prescription for weight reduction for $50 a month. It is a notable shift for Medicare, which has lengthy been barred from protecting weight reduction therapies.
The medicine, comparable to Wegovy and Zepbound, are efficient however will be costly with out insurance coverage protection. They’re obtainable in injection or tablet type. Even with reductions, present money costs usually vary from $149 to $699 per 30 days.
About half of GLP-1 customers say these medicine have been troublesome for them to afford, in response to KFF polling. 1 / 4 mentioned they have been “very troublesome” to afford.
However the brand new Medicare profit comes with caveats, significantly round scientific pointers and what occurs when the short-term program ends.
What is that this program?
The initiative, introduced by the Facilities for Medicare & Medicaid Companies, or CMS, is a short-term pilot program generally known as the Medicare GLP-1 Bridge. It should run from July 1, 2026, by Dec. 31, 2027. It is meant to “bridge” the hole earlier than a longer-term program which may — or won’t — start in 2028.
The pilot program will supply protection for the next GLP-1 medicines permitted for weight reduction: the tablet and injectable formulations of Wegovy, the KwikPen formulation of Zepbound, and the Foundayo tablet.
Who can take part?
To get entry to those weight reduction medicines, you should be enrolled in a Medicare Half D plan, which covers prescribed drugs. After that, eligibility is predicated primarily on physique weight and well being standing. Individuals will qualify if they’ve a physique mass index of 27 or larger and have a situation comparable to coronary heart illness or prediabetes, amongst others. Individuals with BMIs of 35 or larger mechanically qualify. About 40% of American adults are clinically overweight, with a BMI of 30 or larger, in response to the Facilities for Illness Management and Prevention.
How this system works (it’s kind of uncommon)
This isn’t your typical Medicare profit. Regardless that Half D enrollment is required, the Bridge program itself works in a different way.
As an alternative of going by your common Half D plan, you’ll need prior authorization. Your physician will ship the prescription to a central system run by CMS contractor Humana, utilizing a system already in place for one more Medicare drug program. Medical doctors do not must be enrolled as Medicare suppliers to write down a prescription or submit a previous authorization request underneath this program. As soon as they get approval, sufferers can pay the flat $50 copayment on the pharmacy after they choose up the prescription.
What are the advantages?
The fee financial savings may make these medicine accessible to sufferers who merely could not afford them earlier than. Even with reductions, the costs will be daunting with out insurance coverage protection. TrumpRx, a brand new authorities web site, offers hyperlinks to direct-to-consumer prescription drug reductions for sufferers not utilizing their medical health insurance.
On that web site, Wegovy injectables vary in value from $199 for a decrease dosage for the primary two months to $399 for a better dosage. The KwikPen formulation of Zepbound prices as much as $699 per 30 days. On the highest dosages, the each day Wegovy tablet prices as much as $299 whereas Foundayo tops out at $349.
Most individuals who use these medicine will want a better dose to keep up weight reduction. The Bridge program is exclusive in that it presents a predictable $50 copayment that doesn’t go up as dosages enhance.
What are the downsides?
Like many pilot packages, there are trade-offs. The $50 copay won’t depend towards the Half D deductible, nor does it depend towards the $2,100 annual out-of-pocket cap on prescription drug prices. The pilot program may also finish in December 2027. Most research have proven that many individuals who cease utilizing the GLP-1 medicine regain weight they misplaced whereas taking them.
It nonetheless could not really feel reasonably priced to folks with low incomes
When you obtain the low-income subsidy, also called the Medicare Further Assist program, you can not use that help for the medicine lined by the GLP-1 Bridge program. For beneficiaries accustomed to paying a $5 or $10 copay for his or her prescription drugs, a $50 copay may nonetheless be a giant monetary barrier.
“Fifty {dollars} a month feels like an important deal in comparison with paying the discounted costs by TrumpRx and these different direct-to-consumer choices, nevertheless it’s some huge cash for someone who’s residing on a $750-a-month Social Safety verify,” mentioned Juliette Cubanski, deputy director of the Program on Medicare Coverage at KFF, a well being data nonprofit that features KFF Well being Information.
The $50 copay is just for weight reduction
When you’re already taking one in every of these medicines for a qualifying situation comparable to Kind 2 diabetes, heart problems threat discount, or sleep apnea, you will proceed to get it by your common Half D plan. Meaning you will pay your plan’s value, which can be larger than the $50 Bridge copay, which means the identical drug may price completely different quantities relying on the explanation it’s prescribed.
When you’re already on a GLP-1 for weight reduction, you might qualify for the Bridge program. Your prescriber might want to attest that you simply met the scientific standards once you first began the treatment. For instance, if you happen to began a GLP-1 in September 2024 with a BMI of 37 however in July 2026 you’ve got misplaced weight and now have a BMI of 34, the prescriber ought to attest within the prior authorization request that you simply met the BMI standards of 35 or over when the GLP-1 remedy began.
What occurs after 2027?
The Trump administration had proposed a two-step method to develop protection of GLP-1s for weight problems in Medicare. The Bridge program was initially deliberate to final six months — after that, the thought was to launch a longer-term program that will shift the price of the medicine from the federal government to insurers. A latest examine discovered the long-term program would have price insurance coverage firms billions of {dollars} within the first 12 months. Not sufficient insurers signed on for the voluntary plan by the April deadline, so CMS as an alternative introduced it will lengthen the Bridge program to 18 months, with a brand new finish date of December 2027.
The transfer will give insurance coverage firms extra information on how many individuals with Medicare get GLP-1 medicine for weight reduction throughout the Bridge program and extra time to barter with the Trump administration.
However extending the Bridge program might be “actually costly” for Medicare, Cubanski mentioned, as a result of this system closely subsidizes the price of the medicine.
“There is not any sense proper now of the price of the Bridge mannequin, however it’s prone to be billions of {dollars} a 12 months in further spending for Medicare,” Cubanski mentioned.
The fee to Medicare will rely largely on how many individuals use the Bridge program. CMS has not supplied any projections publicly, however a earlier KFF evaluation estimated that in 2020 near 14 million Medicare beneficiaries have been chubby or overweight.
“It will simply price further cash, and we do not understand how a lot, as a result of they have not disclosed it,” Cubanski mentioned.
Are you on Medicare and eager about getting a GLP-1 for weight reduction? Is a $50 copay manageable? Click on right here to contact KFF Well being Information’ reporting crew.
KFF Well being Information is a nationwide newsroom that produces in-depth journalism about well being points and is likely one of the core working packages at KFF.
